FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast CancerAMIRI-KORDESTANI, Laleh; BLUMENTHAL, Gideon M; RUSSELL, Anne M et al.Clinical cancer research (Print). 2014, Vol 20, Num 17, pp 4436-4441, issn 1078-0432, 6 p.Article

Les anticorps conjugués en oncologie: du concept au trastuzumab emtansine (T-DM1) = Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)GONCALVES, Anthony; TREDAN, Olivier; VILLANUEVA, Christian et al.Bulletin du cancer. 2012, Vol 99, Num 12, pp 1183-1191, issn 0007-4551, 9 p.Article

The Safety of Concentrated Trastuzumab in 100 ml of Saline Solution for Administration to Patients with HER2-Positive Breast Cancer: A Phase 1 StudySENGOKU, Norihiko; TANINO, Hirokazu; WATANABE, Masahiko et al.Chemotherapy (Basel). 2014, Vol 60, Num 1, pp 1-6, issn 0009-3157, 6 p.Article

trastuzumab emtansine ^(KADCYLA°) : Une combinaison de cytotoxiques trop peu évaluéeLa Revue Prescrire. 2014, Vol 34, Num 371, issn 0247-7750, p. 656Article

ScFv-Decorated PEG-PLA-Based Nanoparticles for Enhanced siRNA Delivery to Her2⁺ Breast CancerSHUANG DOU; YANG, Xian-Zhu; XIONG, Meng-Hua et al.Advanced healthcare materials (Print). 2014, Vol 3, Num 11, pp 1792-1803, issn 2192-2640, 12 p.Article